1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. MABの機能によるスニペット
3.2. MABの構造によるスニペット
3.3. 技術別スニペット
3.4. アプリケーション別スニペット
3.5. エンドユーザー別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性疾患の増加
4.1.2. 阻害要因
4.1.2.1. 開発・治療コストの高さ
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 償還分析
5.6. 特許分析
5.7. SWOT分析
5.8. DMI意見
6. MABの機能別
6.1. はじめに
6.1.1. MAB機能別の市場規模分析と前年比成長率分析（%）。
6.1.2. 市場魅力度指数（MAB機能別
6.2. ネイキッドモノクローナル抗体
6.2.1. はじめに
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 共役モノクローナル抗体
6.4. 二重特異性モノクローナル抗体
7. MAB構造別
7.1. はじめに
7.1.1. MAB構造別の市場規模分析と前年比成長率分析(%)
7.1.2. 市場魅力度指数（MAB構造別
7.2. ムライン
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. キメラ
7.4. ヒト化
7.5. ヒト
8. 技術別
8.1. 導入
8.1.1. 市場規模分析および前年比成長率分析(%), 技術別
8.1.2. 市場魅力度指数（流通チャネル別
8.2. ハイブリドーマ技術
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. ファージディスプレイ
8.4. 単一B細胞抗体技術
8.5. 組み換え抗体作製
9. 地域別
9.1. 導入
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. MAB機能別の市場規模分析および前年比成長率分析（%） 9.2.4.
9.2.4. 市場規模分析および前年比成長率分析 (%)、MAB構造別
9.2.5. 市場規模分析および前年比成長率分析（%）, 技術別
9.2.6. 市場規模分析および前年比成長率分析 (%)、用途別
9.2.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.2.8. 市場規模分析および前年比成長率分析(%)、国別
9.2.8.1. 米国
9.2.8.2. カナダ
9.2.8.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. MAB機能別の市場規模分析および前年比成長率分析（%） 9.3.4.
9.3.4. 市場規模分析および前年比成長率分析 (%)、MAB構造別
9.3.5. 市場規模分析および前年比成長率分析 (%)、技術別
9.3.6. 市場規模分析および前年比成長率分析 (%)、用途別
9.3.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.3.8. 市場規模分析および前年比成長率分析(%)、国別
9.3.8.1. ドイツ
9.3.8.2. イギリス
9.3.8.3. フランス
9.3.8.4. イタリア
9.3.8.5. スペイン
9.3.8.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. MAB機能別の市場規模分析および前年比成長率分析（%） 9.4.4.
9.4.4. 市場規模分析および前年比成長率分析 (%)、MAB構造別
9.4.5. 市場規模分析および前年比成長率分析 (%)、技術別
9.4.6. 市場規模分析および前年比成長率分析 (%)、用途別
9.4.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.4.8. 市場規模分析および前年比成長率分析(%)、国別
9.4.8.1. ブラジル
9.4.8.2. アルゼンチン
9.4.8.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. MAB機能別の市場規模分析および前年比成長率分析（%） 9.5.4.
9.5.4. 市場規模分析および前年比成長率分析（%）、MAB構造別
9.5.5. 市場規模分析および前年比成長率分析（%）, 技術別
9.5.6. 市場規模分析および前年比成長率分析 (%)、用途別
9.5.7. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
9.5.8. 市場規模分析および前年比成長率分析(%)、国別
9.5.8.1. 中国
9.5.8.2. インド
9.5.8.3. 日本
9.5.8.4. 韓国
9.5.8.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. MAB機能別の市場規模分析および前年比成長率分析（%） 9.6.4.
9.6.4. 市場規模分析および前年比成長率分析 (%)、MAB構造別
9.6.5. 市場規模分析および前年比成長率分析（%）, 技術別
9.6.6. 市場規模分析および前年比成長率分析 (%)、用途別
9.6.7. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Amgen Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Biogen
11.3. Bristol-Myers Squibb Company
11.4. Eli Lilly and Company
11.5. F. Hoffmann-La Roche Ltd
11.6. GlaxoSmithKline plc
11.7. Novartis AG
11.8. Pfizer Inc.
11.9. Sanofi
11.10. Merck & Co., Inc.
リストは網羅的ではありません
12. 付録
12.1. メルクについて
12.2. お問い合わせ

Overview
The global in vitro monoclonal antibodies market reached US$ 5.41 billion in 2023 and is expected to reach US$ 8.4 billion by 2031, growing at a CAGR of 5.7% during the forecast period 2024-2031.
Monoclonal antibodies (mAbs) are laboratory-engineered proteins that mimic the immune system's ability to neutralize harmful microbes including viruses and cancer cells. They are produced by cloning a single white blood cell, yielding identical antibodies that target a specific epitope on an antigen. Monoclonal antibodies have numerous and significant applications in both diagnostic and therapeutic fields. In medicine, they are commonly used to diagnose and treat a variety of diseases, including cancer, autoimmune disorders, and infectious infections.
The global in vitro monoclonal antibodies market is driven by the increasing prevalence of chronic diseases. For instance, according to the Pan American Health Organization, globally, there were an expected 20 million new cancer diagnoses and 10 million cancer deaths. Over the next two decades, the cancer burden will rise by almost 60%, putting a further burden on healthcare systems, individuals, and communities.

Market Dynamics: Drivers & Restraints
Increasing prevalence of chronic diseases
The increasing prevalence of chronic diseases is expected to be a significant factor in the growth of the global in vitro monoclonal antibodies market. Due to the increasing prevalence of various chronic diseases such as cancer, autoimmune diseases, chronic eye diseases, bone-related diseases, and inflammatory diseases, the demand for their treatment by using various monoclonal antibodies for various treatments increases which drives the monoclonal antibodies market.
For instance, according to the National Institute of Health, in 2023, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths. Prostate cancer incidence climbed by 3% every year from 2014 to 2019, after two decades of reduction, resulting in an additional 99,000 new cases. The annual cancer incidence rate is 440.5 per 100,000 men and women (based on cases from 2017 to 2021). The cancer death rate (cancer mortality) is 146.0 per 100,000 men and women annually (based on deaths from 2018-2022). In 2024, a projected 14,910 children and adolescents between the ages of 0 and 19 will be diagnosed with cancer, with 1,590 deaths from the condition.

High costs of development and treatment
Factors such as high costs of development and treatment are expected to hamper the global in vitro monoclonal antibodies market. For instance, according to the National Institute of Health, The average annual price of a mAb was $96,731, more than $100,000 for 34 mAb-indication combinations. Oncology and hematology mAbs accounted for 40% of all mAb-indication combinations approved, but more than 85% of those priced at $100,000 or above. The annual cost of mAb treatments in cancer and hematology is approximately $100,000 greater than in other disease conditions. Thus owing to the above factors, the market is expected to restrain over the forecast period.

Segment Analysis
The global in vitro monoclonal antibodies market is segmented based on MAB functionality, MAB structure, technology, application, end-user, and region

Technology:
Hybridoma technology segment is expected to dominate the in vitro monoclonal antibodies market share
The hybridoma technology segment is expected to dominate the global in vitro monoclonal antibodies market share due to its proven efficacy, dependability, and high specificity of the monoclonal antibodies (mAbs) produced. This approach combines antibody-producing B lymphocytes from immunized animals with immortal myeloma cells, creating hybrid cells that may reproduce indefinitely while producing huge amounts of a specific antibody. One of the most significant advantages of hybridoma technology is its ability to produce very pure and constant mAbs.
For instance, more than 90% of all therapeutic mAbs approved by the FDA today are produced from hybridoma technology, demonstrating its dominance in the area.
Single B-cell antibody technology segment is the fastest growing segment in the in vitro monoclonal antibodies market share.
Single B-cell antibody technology segment is the fastest growing segment in the global in vitro monoclonal antibodies market. This novel strategy has gained popularity because of its capacity to quickly identify and manufacture highly specific antibodies from individual B cells, which is critical for developing targeted therapeutics for a variety of diseases, including cancer and autoimmune disorders. It enables researchers to isolate and analyse antibodies directly from an individual's immunological repertoire, resulting in the discovery of unusual and high-affinity antibodies that would not be easily accessible using standard approaches.

Application:
Oncology segment is expected to dominate the global in vitro monoclonal antibodies market share
The oncology segment is expected to hold the dominant position in the global in vitro monoclonal antibodies market share. This is due to the increasing incidence of cancer, the increasing number of approvals, and extensive research work on cancer treatment using MABs. The high prevalence of cancer increases the demand for the treatment and makes oncology the dominating segment.
For instance, in May 2024, The FDA has approved Trastuzumab Deruxtecan for any HER2-positive solid cancer. T-DXd is the first cancer therapy (antibody-drug conjugate) to be approved for "tumor agnostic" use. T-DXd is already licensed to treat a variety of malignancies, including breast and stomach.

Autoimmune diseases are the fastest growing segment in the global in vitro monoclonal antibodies market share
The rapid growth of the autoimmune diseases segment in the global in vitro monoclonal antibodies market can be attributed to the increasing prevalence of autoimmune diseases and recent breakthroughs in biotechnology have resulted in the development of highly targeted mAb treatments capable of modulating immune responses. These medicines provide a more specific approach to treatment, which improves patient results while minimizing side effects.
For instance, in June 2024, Johnson & Johnson announced that it had submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for approval of TREMFYA (guselkumab) for the treatment of individuals with moderately to severely active Crohn's disease. TREMFYA is the first approved fully human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, a receptor on cells that makes IL-23.5 IL-23, a cytokine released by activated monocytes/macrophages and dendritic cells, is recognized to be a driver of immune-mediated conditions.

Geographical Analysis
North America is expected to hold a significant position in the global in vitro monoclonal antibodies market share
North America is expected to hold a significant position in the market share during the forecast period. The rising incidence of chronic diseases, and recent launches, in this region, help to propel the market. So, as the prevalence of chronic diseases increases, the demand for the treatment of chronic diseases by monoclonal antibodies gradually gets upsurged which drives the global in vitro monoclonal antibodies market.
For instance, according to an article published by the National Institute of Health, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.
Moreover, according to the National Health Council, Autoimmune conditions affect more than 50 million Americans. Furthermore, autoimmunity has reached pandemic proportions, with some studies suggesting an annual increase of 3-12%. Over the last 30 years, the prevalence of celiac disease in the United States has increased fivefold, roughly doubling every 15 years.

Asia Pacific is growing at the fastest pace in the global in vitro monoclonal antibodies market
Asia Pacific is experiencing the fastest growth in the global in vitro monoclonal antibodies market. The rapid expansion of the ADHD market in the Asia Pacific is being driven by the rising incidence of chronic diseases, increasing healthcare access, increased investments in the research and development of in vitro monoclonal antibodies, and recent launches.
For instance, according to the National Institute of Health, the expected number of cancer cases in India for 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one out of every nine people is likely to develop cancer over his or her lifetime. Males and females were most likely to develop lung and breast cancer, respectively.

Competitive Landscape
The major global players in the global in vitro monoclonal antibodies market include Amgen Inc., Biogen, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc. among others.

Emerging Players
Zenas BioPharma, Inc., Aulos Bioscience, and Alentis Therapeutics AG among others.

Key Developments
 In January 2023, Amgen announced that AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. The US Food and Drug Administration (FDA) authorized AMJEVITA as the first Humira biosimilar. AMJEVITA is a biosimilar of Humira®* (adalimumab), an anti-TNF-α monoclonal antibody. AMJEVITA contains an anti-TNF-α monoclonal antibody, which shares the same amino acid sequence as Humira.
 In April 2024, Pfizer Inc. and Genmab A/S announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. TIVDAK (tisotumab vedotin-tftv) is an antibody-drug conjugate (ADC) made up of Genmab's human monoclonal antibody directed to tissue factor (TF) and Pfizer's ADC technology, which uses a protease-cleavable linker to covalently attach the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody.

Why Purchase the Report?
• To visualize the global in vitro monoclonal antibodies market segmentation based on MAB functionality, MAB structure, technology, application, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global in vitro monoclonal antibodies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global in vitro monoclonal antibodies market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by MAB Functionality
3.2. Snippet by MAB Structure
3.3. Snippet by Technology
3.4. Snippet by Application
3.5. Snippet by End-User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Chronic Diseases
4.1.2. Restraints
4.1.2.1. High Costs of Development and Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By MAB Functionality
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality
6.1.2. Market Attractiveness Index, By MAB Functionality
6.2. Naked Monoclonal Antibodies*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Conjugated Monoclonal Antibodies
6.4. Bispecific Monoclonal Antibodies
7. By MAB Structure
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure
7.1.2. Market Attractiveness Index, By MAB Structure
7.2. Murine*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chimeric
7.4. Humanized
7.5. Human
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hybridoma technology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Phage display
8.4. Single B-cell antibody technology
8.5. Recombinant antibody production
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.8.1. The U.S.
9.2.8.2. Canada
9.2.8.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.8.1. Germany
9.3.8.2. UK
9.3.8.3. France
9.3.8.4. Italy
9.3.8.5. Spain
9.3.8.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.8.1. Brazil
9.4.8.2. Argentina
9.4.8.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.8.1. China
9.5.8.2. India
9.5.8.3. Japan
9.5.8.4. South Korea
9.5.8.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Amgen Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Biogen
11.3. Bristol-Myers Squibb Company
11.4. Eli Lilly and Company
11.5. F. Hoffmann-La Roche Ltd
11.6. GlaxoSmithKline plc
11.7. Novartis AG
11.8. Pfizer Inc.
11.9. Sanofi
11.10. Merck & Co., Inc.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

※参考情報 体外モノクローナル抗体とは、特定の抗原に対して高い特異性と恒常性を持つ抗体であり、特定のB細胞を選択的に増殖させて得られたものです。通常、マウスやラットの脾臓からのB細胞を使用し、融合技術により得られるハイブリドーマ細胞によって生成されます。このプロセスにより、特定の抗原に特異的かつ連続的に抗体を生成することができます。体外で生産されるモノクローナル抗体は、研究だけでなく、臨床診断や治療にも広く利用されています。 体外モノクローナル抗体には、主に二つの種類があります。一つは、マウス由来のモノクローナル抗体で、従来から多くの研究や治療に用いられてきました。もう一つは、ヒト化モノクローナル抗体で、これはマウスの抗体をベースにしてヒトの免疫系に適合するように改良されたものです。ヒト化モノクローナル抗体は、免疫反応が低減し、アレルギー反応のリスクが少ないため、特に臨床使用において好まれています。 体外モノクローナル抗体の用途は多岐にわたります。研究の場では、細胞の機能解析や病気のメカニズムの解明に利用されます。例えば、特定の細胞表面マーカーを認識するモノクローナル抗体を用いて、細胞の種類や状態を特定することができます。また、疾患の診断にも利用され、多くの血液検査や病理診断で重要な役割を担っています。アンチ体による技術は、例えばELISAやフローサイトメトリーなどで利用されます。 さらに、モノクローナル抗体は治療にも使用されます。がん治療においては、がん細胞特有の抗原をターゲットにした抗体療法が開発されており、これにより選択的にがん細胞を攻撃することが可能です。自己免疫疾患や感染症、アレルギーの治療においても利用され、特定の病気に対して効果を示す抗体が次々と開発されています。 関連技術としては、ハイブリドーマ技術が挙げられます。これは、抗体を生成するB細胞と、永続的に増殖可能な細胞（通常はがん細胞）を融合させる技術です。これにより、特定の抗原に対する抗体を無限に生産できる細胞株が得られます。また、遺伝子工学技術を用いることで、抗体の構造を改良したり、特異性を高めることも可能です。これにより、新たな治療法や診断法が次々と登場しています。 最近では、国際的な基準に基づいたモノクローナル抗体の評価法も確立され、品質管理や標準化が進んでいます。これにより、信頼性の高い抗体が提供されるようになり、研究や臨床での使用においても安心感が増しています。 今後も体外モノクローナル抗体は、医療や研究のさまざまな場面で重要な役割を果たしていくことでしょう。特に、新たな疾病の発生や治療法の進展が期待される中で、この技術はますます進化し続けると考えられます。抗体の特異性とその多様性を活用することで、新しい治療の可能性が開け、医療の現場での応用が期待されています。

❖ 世界の体外モノクローナル抗体市場に関するよくある質問(FAQ) ❖

・体外モノクローナル抗体の世界市場規模は？
→DataM Intelligence社は2023年の体外モノクローナル抗体の世界市場規模を54億1,000万米ドルと推定しています。

・体外モノクローナル抗体の世界市場予測は？
→DataM Intelligence社は2031年の体外モノクローナル抗体の世界市場規模を84億米ドルと予測しています。

・体外モノクローナル抗体市場の成長率は？
→DataM Intelligence社は体外モノクローナル抗体の世界市場が2024年～2031年に年平均5.7%成長すると予測しています。

・世界の体外モノクローナル抗体市場における主要企業は？
→DataM Intelligence社は「Amgen Inc., Biogen, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc.など ...」をグローバル体外モノクローナル抗体市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。